Pamidronate Attenuates Muscle Loss After Pediatric Burn Injury

Authors

  • Elisabet Børsheim,

    1. Department of Surgery, University of Texas Medical Branch, Galveston, TX, USA
    2. Shriners Hospital for Children, Galveston, TX, USA
    Search for more papers by this author
  • David N Herndon,

    1. Department of Surgery, University of Texas Medical Branch, Galveston, TX, USA
    2. Shriners Hospital for Children, Galveston, TX, USA
    Search for more papers by this author
  • Hal K Hawkins,

    1. Shriners Hospital for Children, Galveston, TX, USA
    2. Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA
    Search for more papers by this author
  • Oscar E Suman,

    1. Department of Surgery, University of Texas Medical Branch, Galveston, TX, USA
    2. Shriners Hospital for Children, Galveston, TX, USA
    Search for more papers by this author
  • Matthew Cotter,

    1. Department of Surgery, University of Texas Medical Branch, Galveston, TX, USA
    2. Shriners Hospital for Children, Galveston, TX, USA
    Search for more papers by this author
  • Gordon L Klein

    Corresponding author
    1. Shriners Hospital for Children, Galveston, TX, USA
    2. Department of Orthopaedic Surgery and Rehabilitation, University of Texas Medical Branch, Galveston, TX, USA
    • Address correspondence to: Gordon L Klein, MD, Department of Orthopaedic Surgery and Rehabilitation, University of Texas Medical Branch, Galveston, TX 77555, USA. E-mail: gordonklein@ymail.com

    Search for more papers by this author

  • Presented in part at the 35th Annual Meeting of the American Society for Bone and Mineral Research, Baltimore, MD, October 4–7, 2013.

ABSTRACT

Children who are burned >40% total body surface area lose significant quantities of both bone and muscle mass because of acute bone resorption, inflammation, and endogenous glucocorticoid production, which result in negative nitrogen balance. Because administration of the bisphosphonate pamidronate within 10 days of the burn injury completely prevents the bone loss, we asked whether muscle protein balance was altered by the preservation of bone. We reviewed the results from 17 burned pediatric subjects previously enrolled in a double-blind randomized controlled study of pamidronate in the prevention of post-burn bone loss and who were concurrently evaluated for muscle protein synthesis and breakdown by stable isotope infusion studies during the acute hospitalization. We found a significantly lower fractional protein synthesis rate (FSR) in the pamidronate group and a correspondingly lower rate of appearance of the amino acid tracer in venous blood, suggesting lower muscle protein turnover. Moreover, net protein balance (synthesis minus breakdown) was positive in the subjects receiving pamidronate and negative in those receiving placebo. Muscle fiber diameter was significantly greater in the pamidronate subjects and leg strength at 9 months post-burn was not different between subjects who received pamidronate and normal physically fit age-matched children studied in our lab. Leg strength in burned subjects who served as controls tended to be weaker, although not significantly so. If substantiated by a larger study, these results suggest that bone may have a paracrine mechanism to preserve muscle and this finding may have implications for the treatment of sarcopenia in the elderly. © 2014 American Society for Bone and Mineral Research.

Ancillary